This page lists the cancer care hospitals in our directory offering Anal Cancer Treatment in Dubai, UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about anal cancer treatment in Dubai, UAE
Share a few details and our care coordination team will get back to you with next steps.
Compare 3 accredited hospitals for Cancer Care in Dubai, UAE
Featured🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Ranks #1 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Kings College Hospital Dubai
Ranks #2 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Aster Hospital Dubai
Ranks #3 in this list by listed rating (4.5/5 from 1 reviews).
How we selected these hospitals
A hospital appears on this page when Cancer Care is among its listed specialties and it is located in Dubai, UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Anal Cancer Treatment in Dubai, UAE?
Choosing the right hospital for anal cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cancer care rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Anal Cancer Treatment
Anal cancer, though relatively rare, is a highly treatable malignancy when detected early, with modern chemoradiation protocols achieving organ-preservation rates exceeding 80% and overall five-year survival rates of 65–90% depending on stage. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centres in India and JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi, offering world-class multidisciplinary care at a fraction of Western costs. Whether you require definitive chemoradiation therapy, sphincter-preserving surgery, or salvage abdominoperineal resection (APR), GAF Healthcare's end-to-end coordination ensures a seamless, medically rigorous experience from first consultation to post-treatment follow-up. Hospital Stay: 7–21 days (varies by treatment modality: 7–10 days for surgical cases; chemoradiation delivered largely on an outpatient basis over 5–6 weeks) • Total Stay in Country (Fit-to-Fly): 6–8 weeks after completion of chemoradiation; 4–6 weeks after surgical resection (subject to oncologist clearance and wound healing status) • Success Rate: 75–90% (stage-dependent; Stage I–II five-year survival 80–90%; Stage III approximately 60–70%; salvage surgery after recurrence 30–50%)
Clinical Overview
Anal cancer arises from the epithelial lining of the anal canal and perianal skin, with squamous cell carcinoma (SCC) accounting for approximately 80–85% of all cases. Less common histologies include adenocarcinoma (originating near the anorectal junction), basaloid carcinoma, small cell carcinoma, and melanoma. The anal canal, a 3–4 cm muscular tube connecting the rectum to the perianal skin, is a functionally critical structure housing the internal and external anal sphincters; malignant infiltration therefore carries significant implications for continence, quality of life, and pelvic organ function. Risk factors include persistent infection with high-risk human papillomavirus (HPV) genotypes 16 and 18, HIV infection and associated immunosuppression, a history of receptive anal intercourse, cigarette smoking, and prior cervical or vulvar dysplasia or cancer. Diagnosis is established by clinical examination, high-resolution anoscopy, and biopsy, with staging completed via pelvic MRI, CT of the chest/abdomen/pelvis, and FDG-PET/CT scan to detect nodal and distant metastases. The physiological impact of anal cancer and its treatment is multidimensional. Locally advanced tumours may invade the sphincter complex, vagina, urethra, or prostate, causing fistulae, urinary obstruction, and faecal incontinence. Definitive concurrent chemoradiation therapy (CRT) — the internationally established standard of care per NCCN, ESMO, and ACR guidelines — targets the primary tumour and regional lymph nodes while aiming to preserve sphincter function, avoiding the permanent colostomy associated with abdominoperineal resection (APR). The landmark ACT I and ACT II trials established mitomycin-C (MMC) plus 5-fluorouracil (5-FU) concurrently with external beam radiotherapy (EBRT) as the backbone regimen, achieving complete response in 60–70% of patients. Radiation doses of 45–59.4 Gy are delivered using intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimise dose to adjacent bowel, bladder, and femoral heads. The global standard of care for non-metastatic anal SCC is definitive CRT with MMC/5-FU or capecitabine-based regimens; surgery is reserved for residual or recurrent disease following CRT failure. Metastatic or refractory disease is increasingly managed with platinum-based chemotherapy (carboplatin/paclitaxel) and, for MSI-high or PD-L1-positive tumours, immune checkpoint inhibitors such as pembrolizumab (anti-PD-1) or nivolumab, both of which have demonstrated durable responses in anal SCC. Multidisciplinary tumour board evaluation — involving medical oncology, radiation oncology, colorectal surgery, radiology, pathology, and gastroenterology — is the foundational governance model at all GAF Healthcare partner institutions in India and the UAE.
Who is a Candidate?
• ELIGIBLE PATIENTS: • Adults with biopsy-confirmed anal canal or perianal squamous cell carcinoma, adenocarcinoma, or other histologies at any stage (T1–T4, N0–N3, M0–M1) • Patients with HIV who have a CD4 count ≥200 cells/µL and are on stable antiretroviral therapy (ART); CRT is feasible with appropriate haematological monitoring • Patients with resectable or potentially resectable residual/recurrent disease after primary CRT who are candidates for salvage APR • Patients with oligometastatic disease being considered for systemic therapy combined with local ablative treatment (stereotactic body radiotherapy — SBRT — to liver or lung metastases) • Patients seeking a second opinion on staging, treatment planning, or recurrence management • REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL: • Pathology report (biopsy slides or paraffin blocks) with HPV status, p16 immunohistochemistry, and tumour histology • Pelvic MRI with contrast (ideally 1.5T or 3T): essential for T-staging, sphincter involvement, and nodal assessment • FDG-PET/CT scan (whole body): for nodal and distant metastasis evaluation; required for accurate IMRT target volume delineation • CT chest/abdomen/pelvis with contrast (if PET-CT not available) • Full blood count, renal function (eGFR ≥45 mL/min required for platinum-based regimens), liver function tests, serum albumin • HIV serology, CD4 count, and HIV viral load (mandatory) • HPV genotyping (16/18 preferred) • Echocardiogram (ECHO) if baseline cardiac compromise suspected or prior cardiotoxic chemotherapy received • Audiogram if cisplatin-based therapy is planned • Pulmonary function tests (PFTs) if thoracic SBRT is considered • CONTRAINDICATIONS / SPECIAL CONSIDERATIONS: • Active inflammatory bowel disease (Crohn's or ulcerative colitis) involving the anorectum: significantly increases CRT toxicity risk; requires specialist gastroenterology co-management • Prior high-dose pelvic radiotherapy: limits re-irradiation capacity; salvage surgery may be the only curative option • Severe uncontrolled immunosuppression (CD4 <100 cells/µL, uncontrolled HIV viral load): CRT must be deferred until immune reconstitution • Active fistula or septic pelvic infection: requires surgical drainage/defunctioning colostomy before CRT can commence • Pregnancy: CRT is absolutely contraindicated; surgical options with multidisciplinary counselling are considered on a case-by-case basis • WHO/ECOG performance status ≥3 or severe baseline organ dysfunction may preclude aggressive curative-intent therapy
Treatment Options & Approaches
DEFINITIVE CONCURRENT CHEMORADIATION THERAPY (CRT) — STANDARD OF CARE: For non-metastatic anal SCC (Stages I–III), definitive CRT is the primary curative strategy, sparing the anal sphincter and avoiding permanent colostomy in the majority of patients. The internationally validated regimen consists of: • Radiation Therapy: External beam radiotherapy (EBRT) at 45–50.4 Gy to the pelvis and regional nodes, with a sequential or simultaneous integrated boost (SIB) to the primary tumour to a total dose of 54–59.4 Gy, delivered over approximately 28–33 fractions (5.5–6.5 weeks). • Delivery Technology: All GAF Healthcare partner centres employ Intensity-Modulated Radiotherapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT) to achieve highly conformal dose distribution, reducing acute toxicity (proctitis, cystitis, dermatitis, small bowel toxicity) compared to older 3D-CRT techniques. Image-Guided Radiotherapy (IGRT) with daily cone-beam CT is standard. • Chemotherapy Backbone (Concurrent): Mitomycin-C (MMC) 10–12 mg/m² IV bolus on Days 1 and 29 + 5-Fluorouracil (5-FU) 1000 mg/m²/day as a continuous 96-hour infusion on Days 1–4 and 29–32. Alternatively, oral capecitabine (825 mg/m² twice daily on radiation days) is used as an evidence-based, more convenient substitute for 5-FU (UKCCCR ACT II data). SURGICAL APPROACHES: • Local Excision (Wide Local Excision / WLE): Reserved for small (≤2 cm), superficial T1 N0 tumours that do not involve the sphincter. Achieves R0 margins with sphincter preservation; cure rates >90% for appropriately selected tumours. Performed under general or spinal anaesthesia with transanal access. • Abdominoperineal Resection (APR): The definitive surgical procedure for CRT failure, residual disease at 26-week post-CRT assessment, or recurrent anal cancer. Involves en-bloc removal of the rectum, anus, levator ani muscles, and surrounding perineal tissue, with construction of a permanent end colostomy. Robotic-assisted APR (using da Vinci Surgical System) is available at select partner centres, offering superior perineal dissection with 3D visualisation, reduced blood loss, and improved autonomic nerve preservation compared to conventional open APR — particularly beneficial in the previously irradiated, scarred pelvis. Extralevator APR (ELAPE) is performed for locally advanced T3–T4 tumours to achieve wider circumferential resection margins and reduce the risk of intraoperative perforation. • Defunctioning Loop Colostomy: A palliative or bridging procedure performed laparoscopically to relieve faecal obstruction caused by bulky tumours or to protect the perianal skin during CRT in patients with severe pre-existing anal pathology or fistulae. This is not a curative intervention. • Pelvic Exenteration: For ultra-locally advanced tumours invading the bladder, urethra, or vagina; performed at high-volume pelvic oncology centres with multidisciplinary reconstructive teams. SYSTEMIC THERAPY FOR METASTATIC / REFRACTORY DISEASE: • First-line: Carboplatin (AUC 5) + Paclitaxel (80 mg/m² weekly or 175 mg/m² every 3 weeks); this combination demonstrated superiority over cisplatin/5-FU in the InterAACT randomised trial with improved tolerability. • Immunotherapy: Pembrolizumab (200 mg IV every 3 weeks) is FDA- and EMA-approved for MSI-high or PD-L1 CPS ≥10 anal SCC in the second-line setting (KEYNOTE-158 data, ORR ~12–16% in unselected, higher in biomarker-selected). Nivolumab has shown similar activity. PDL1/MSI-H/TMB-H biomarker testing (next-generation sequencing — NGS panel) is strongly recommended at diagnosis for all metastatic cases. • HER2-Directed Therapy: Trastuzumab-based regimens are under evaluation for HER2-amplified anal adenocarcinoma in clinical trials. • SBRT / Ablation for Oligometastases: For patients with 1–3 liver or lung metastases and controlled primary disease, stereotactic body radiotherapy (SBRT) or radiofrequency ablation (RFA) may be offered with curative or progression-delay intent. INDUCTION AND NEOADJUVANT STRATEGIES: • Induction chemotherapy with carboplatin/paclitaxel × 2 cycles prior to CRT is under active investigation (CCTG CO.26-style protocols) for bulky T3–T4 or N3 disease to reduce tumour burden before definitive radiotherapy.
Recovery
PHASE 1 — PRE-TRAVEL & REMOTE CONSULTATION (Weeks 1–2): • Step 1: Submit all diagnostic records (biopsy pathology, MRI, PET-CT, blood results) to GAF Healthcare's oncology coordination team via the secure patient portal. • Step 2: Virtual multidisciplinary tumour board review by the partner hospital team (medical oncologist, radiation oncologist, colorectal surgeon). A detailed treatment plan and cost estimate are issued within 48–72 hours. • Step 3: GAF Healthcare assists with e-Medical Visa application (India) or coordinates entry visa requirements (UAE). Travel and accommodation arrangements for patient and one attendant are confirmed. PHASE 2 — ARRIVAL & WORKUP (Days 1–5 in country): • Step 4: Airport reception by GAF Healthcare's dedicated patient liaison officer. Transfer to pre-arranged hospital-adjacent accommodation or a private hospital room. • Step 5: Repeat or complementary diagnostics as required: high-resolution anoscopy/EUA (examination under anaesthesia) for precise T-staging, fresh blood work, cardiac ECHO if indicated, nutritional assessment (serum albumin, BMI), and stomatology/dental review if head/neck radiation ports are involved. • Step 6: Radiation Oncology simulation session: CT simulation scan in treatment position with customised immobilisation devices (vacuum-lock bag, knee rest); target volume delineation and IMRT/VMAT treatment plan optimisation (typically requires 3–5 business days of physics planning). • Step 7: Medical oncology consultation to confirm chemotherapy regimen, ensure adequate renal/hepatic function, and insert a PICC line or portacath if continuous 5-FU infusion is planned. PHASE 3 — ACTIVE TREATMENT (Weeks 2–8): • Step 8: CRT commences. Radiation delivered Monday–Friday (5 days/week) over 5.5–6.5 weeks (28–33 fractions). Chemotherapy (MMC bolus on Days 1 and 29; 5-FU infusion on Days 1–4 and 29–32, or daily capecitabine) administered concurrently. • Step 9: Weekly on-treatment reviews with radiation oncologist and medical oncologist to assess acute toxicity (skin desquamation, proctitis, cystitis, mucositis, haematological suppression), manage side effects (topical barrier creams, analgesia, anti-diarrhoeals, G-CSF if required), and perform treatment verification imaging. • Step 10 (Surgical cases only): If proceeding to planned surgical resection (WLE or APR), hospitalisation is typically 7–14 days post-operatively. Stoma nurse education and psychological support for permanent colostomy patients are provided by specialist colorectal nursing teams. PHASE 4 — POST-TREATMENT ASSESSMENT & RECOVERY (Weeks 8–14 in country): • Step 11: Clinical response assessment at 8 weeks post-CRT: digital rectal examination, pelvic MRI, and PET-CT scan. Complete clinical response (cCR) in the primary tumour in approximately 60–70% of patients at this time point; definitive response assessment may continue up to 26 weeks (per ACT II protocol). • Step 12: If cCR is confirmed, active surveillance commences. If residual disease is confirmed at 26 weeks, multidisciplinary discussion regarding salvage APR is initiated. • Step 13: Fit-to-fly assessment. After CRT, most patients can safely travel internationally at 6–8 weeks post-treatment completion, provided acute toxicity has resolved (skin healing, haematological recovery to safe thresholds). After APR, minimum 4–6 weeks with wound healing and stoma stability confirmed. • Step 14: Discharge summary, full imaging and pathology reports in English, and a detailed follow-up protocol (3-monthly clinical review and MRI/PET-CT for 2 years, then 6-monthly for 3 years) are provided to the patient's home oncology team via GAF Healthcare's care coordination platform.
Risks to be aware of
Anal cancer treatment carries a distinct and well-characterised risk profile that varies by modality. Definitive CRT — while sphincter-sparing — produces significant acute toxicity in the majority of patients: Grade 3–4 acute skin reactions (moist desquamation of the perineum and perianal skin) occur in 20–50% of cases; acute proctitis, diarrhoea, cystitis, and haematological toxicity (neutropenia, thrombocytopenia from MMC) are common and require proactive supportive care. Late radiation toxicity is clinically important: chronic proctitis, recto-vaginal or recto-urethral fistula, anal stenosis, and radiation-induced small bowel obstruction may occur months to years after treatment and are more prevalent with total radiation doses >54 Gy. Late genitourinary toxicity includes erectile dysfunction and vaginal dryness or stenosis. Haematological toxicity from concurrent MMC/5-FU requires full blood count monitoring twice weekly during treatment; febrile neutropenia necessitates prompt hospitalisation and IV antibiotics. Salvage APR carries the inherent risks of major pelvic surgery in a previously irradiated field: perineal wound dehiscence occurs in 30–50% of cases (significantly higher than in non-irradiated APR), anastomotic complications (if applicable), ureteric or bladder injury, sexual dysfunction, and the psychological burden of permanent colostomy. Immunotherapy with pembrolizumab or nivolumab carries immune-related adverse events (irAEs) including immune-mediated colitis, pneumonitis, hepatitis, endocrinopathies (thyroiditis, adrenal insufficiency, type 1 diabetes), and — rarely — life-threatening myocarditis. HIV-positive patients on CRT require close monitoring for opportunistic infections; concurrent ART may interact with chemotherapy pharmacokinetics (particularly with protease inhibitors and taxanes). All patients should be counselled regarding the risk of treatment-related infertility and offered fertility preservation consultation (sperm banking, oocyte cryopreservation) prior to commencing any gonadotoxic treatment.
Why GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical logistics to ensure that international patients experience zero administrative burden during their treatment journey. VISA & ENTRY DOCUMENTATION: • India: GAF Healthcare's visa assistance team guides patients through the Indian e-Medical Visa (e-MV) application process, which allows stays of up to 60 days (extendable) and permits one companion attendant on an e-Medical Attendant Visa. Required documents (invitation letter from the treating hospital, diagnosis summary, passport copies) are prepared and submitted on the patient's behalf. Typical approval time is 3–7 business days. • UAE (Dubai / Abu Dhabi): Nationals of approximately 50 countries receive visa-on-arrival or visa-free access to the UAE. GAF Healthcare coordinates Medical Visit Visa applications for patients from countries requiring prior approval, liaising directly with the hospital's international patient department and the UAE immigration authorities. Multi-entry visas are arranged for patients requiring extended or phased treatment. AIRPORT TRANSFERS & GROUND TRANSPORT: • Dedicated GAF Healthcare patient liaison officers meet all incoming patients at the airport (Delhi IGI, Mumbai CSMT, Chennai MAA, Bengaluru KIA, Dubai DXB, or Abu Dhabi AUH) with clearly identified signage. • Accessible, air-conditioned vehicles with wheelchair ramp access are arranged as required. Scheduled transfers between accommodation, hospital, and radiation centre (for daily outpatient radiation appointments) are included in the care coordination package. ACCOMMODATION: • GAF Healthcare maintains preferred-rate agreements with serviced apartments, guesthouses, and hotels within 5–10 minutes of all partner hospitals, with options ranging from comfortable economy to full luxury suites. • All recommended accommodation offers a private room for the patient's attendant, Wi-Fi, laundry access, and access to kitchenette facilities (particularly important during CRT when patients require frequent small meals due to treatment-related nausea and mucositis). DEDICATED TRANSLATORS & CULTURAL LIAISONS: • Certified medical interpreters are available in Arabic, Russian, French, Swahili, Bangla, Tagalog, and other major languages at partner hospitals and for all clinical consultations. • A dedicated GAF Healthcare patient relationship manager is assigned to each case for the entire duration of treatment and remains available via WhatsApp, email, and phone 7 days a week. RECORDS & CONTINUITY OF CARE: • All treatment records — including pathology reports, radiation treatment planning files (DICOM-RT), operative notes, and follow-up imaging — are provided in English in a structured digital format for seamless handover to the patient's home oncologist.
Common questions about Anal Cancer Treatment
What is the cost of anal cancer treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home?
What is the success rate of anal cancer treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Anal Cancer Treatment in Dubai, UAE
Discover the Top Hospitals for Anal Cancer Treatment in Dubai, UAE
This page lists 3 accredited cancer care hospitals in Dubai, UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about anal cancer treatment in Dubai, UAE
How many cancer care hospitals are listed in Dubai, UAE?
How do you choose which hospitals to list?
How much does treatment cost in UAE?
Are there cancer care hospitals for this in other UAE cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for anal cancer treatment in Dubai, UAE.
Contact us to report an inaccuracy on this page.